Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Fusion IP plc       GB00B05L5X50

FUSION IP PLC
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Fusion IP plc : Simcyp develops virtual laboratory mouse for use in cancer and toxicology research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/19/2012 | 11:07am CEST

Sheffield, UK. 18th January 2012. Simcyp Limited , the leader in modelling and simulation of drug-drug interactions in virtual human populations, today announces it has extended its animal models to include a virtual mouse.

Laboratory mice are used extensively in the development of new anti-cancer drugs as well as toxicological studies involving agrochemicals.  This research often involves using mice which have been genetically modified in order to investigate the role that drug metabolising enzymes and transporters play in the accumlation of drugs in the whole animal or in specific tissues.  The Simcyp Mouse provides a virtual environment for evaluating drug disposition which will replace the need for some live animal testing in normal as well as transgenic mice, thus reducing and refining preclinical investigation.

The Simcyp Simulators are mathmatical models linking numerous physiological, genetic and biochemical databases with drug-specific data to produce "real-life" predictions to help optimise drug development.  The ability to create virtual transgenic mice by adding (knocking-in) or deleting (knocking-out) certain genes is a unique feature of this model.

Dr Steve Toon, Executive Director at Simcyp, commented:  "The Simcyp Mouse Simulator is a valuable addition to our portfolio of virtual animal models.  Simcyp Mouse will be an incredibly useful tool for scientists and clinicians developing new anti-cancer drugs helping reduce cost, accelerate development timelines and reduce animal testing.  I am proud that Simcyp is able to make its own contribution to the advancement of cancer research."

Members of the Simcyp Consortium of leading pharmaceutical and biotechnology companies have automatic access to all of Simcyp's preclinical models with the latest release of the Simcyp Population-based Simulator.  Licenses for Simcyp Animal can now also be granted to companies outside of the Consortium including contract research organisations.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FUSION IP PLC
2014FUSION IP : Court Confirmation of Capital Reduction and Effective Date
PU
2014FUSION IP : Exercise of Options
PU
2014FUSION IP : Rule 2.10 Announcement
PU
2014FUSION IP PLC : Rule 2.0 Announcement
PU
2014FUSION IP PLC : Results of the Court Meeting and General Meeting
PU
2014FUSION IP PLC : Further announcement 24th February – Scheme Document
PU
2014FUSION IP PLC : Fusion portfolio company Asalus awarded CE mark for Ultravision
PU
2013FUSION IP PLC : Phase Focus strengthens Board with New Chairman and Directors
PU
2013FUSION IP PLC : Absynth Biologics Limited secures £850,000 funding to develop it..
PU
2013FUSION IP PLC : Fusion portfolio company MedaPhor expands sales into China throu..
PU
More news
Income Statement Evolution
Managers
NameTitle
David Graham Baynes Director
Peter Leonard Grant Director
Gregory Simon Smith Director
Lindsey Jones Financial Controller
Sector and Competitors
1st jan.Capitalization (M$)
FUSION IP PLC0
BLACKROCK2.51%83 727
BANK OF NEW YORK MELLON (THE)5.37%57 356
BLACKSTONE GROUP LP1.62%39 229
STATE STREET CORPORATION0.54%35 861
T. ROWE PRICE GROUP17.86%29 783